OH-PROCTER-&-GAMBLE
14.5.2024 14:01:28 CEST | Business Wire | Press release
Procter & Gamble (NYSE: PG), a Worldwide Olympic and Paralympic Partner, announced plans today to prominently feature superior performing household and personal care brands during the Olympic and Paralympic Games Paris 2024 including Olympic-inspired brand marketing and in-store campaigns, brand-sponsored athlete partnerships, and complimentary products and services for athletes in the Athletes’ Village during Paris 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240514255957/en/
The Village Nursery with Pampers (Photo: Business Wire)
Before and during Paris 2024, more than 30 P&G brands will reach billions of engaged consumers in countries around the world through relevant ways that demonstrate product performance superiority. Inspired by the highest performance of the best athletes in the world, P&G’s household and personal care brands are launching Olympic and Paralympic Games-inspired marketing campaigns featuring the highest performance products that serve people every day, including:
- Pampers empowers little champions on the move with Pampers® NEW Baby-Dry™ Pants, providing a superior fit and protection to win against leaks.
- Ariel’s “Champion of Stain and Odor Removal” campaign is taking care of clothes on and off the field, even in cold and short washing machine cycles which are the toughest cleaning conditions.
- Fairy’s “Tough Stain Cleaning Champion” campaign features its mascot, Mr. Fairy, and demonstrates superior product performance in automatic dishwashers, even in short cycles.
- Venus is launching “The Power of Smooth” campaign to highlight Venus as the razor athletes trust to achieve smooth skin, especially in the last step in their pre-competition routine.
- Gillette, a brand with a strong sports heritage, is bringing to life its long-standing promise of "the best a man can get" through a gold razor for Paris 2024 and a campaign featuring its highest performing Gillette Labs product line.
- Always is the Official Period Product of Paris 2024. The “It's a New Period” campaign is aimed at addressing and eliminating period anxiety in the world of sports through the power of products with superior protection.
- Head & Shoulders “Gold Medal Against Dandruff” features the “I Don’t” campaign, demonstrating how the brand prevents dandruff with an Olympic Games-themed twist.
- Oral-B’s “Brush Like a Champion” campaign leverages the brand's role as the Official Oral Care Products of Paris 2024 to promote the use of Oral-B for cleaner, stronger teeth.
- ZzzQuil’s “Sleep Like an Everyday Champion” campaign promotes better sleep as the key to performing at your best.
“Every day, P&G brands provide consumers with high performance products that they trust to meet their daily household and personal care needs for themselves and their families,” said P&G Chief Brand Officer Marc Pritchard. “That inspired us to prominently feature how those superior performing products serve athletes, families and fans so they can focus on achieving their personal best whether on the Olympic or Paralympic stage or in those everyday moments in life that matter.”
These P&G brand marketing campaigns and more will be supported by in-store and online retail activations across more than 150 retailers in more than 40 countries around the world. Over the last several Games, P&G and retailers have worked together to develop the Olympic and Paralympic Games into a highly relevant platform for engaging consumers to drive growth and value creation. The Games are particularly relevant in the host region and for Paris 2024, P&G brands are activating in retail stores across Europe behind the “Everyday Champions” campaign, providing products that give their best every day to meet the household and personal care needs of athletes, families, and fans – just like Olympians and Paralympians give their best to their sport.
During the Games, P&G brands will be providing more complimentary services and products to athletes than ever before, so they can focus on achieving their best when they step out on the world’s biggest stage. P&G brands will meet the everyday demands of more than 22,000 athletes and their staff within the Athletes’ Village, offering accessible and inclusive products and services, including:
- The Village Nursery with Pampers: For the first time in the Olympic and Paralympic Games, Pampers® is creating a comfortable and convenient environment for athlete parents to connect with their babies and young children to enjoy precious moments together in the Athletes’ Village during Paris 2024. The nursery will provide a space for playtime and family bonding and cater to all babies and their diapering needs with Pampers highest quality diapers and wipes.
- Beauty & Grooming Salon by Pantene®, Head & Shoulders®, Mielle®, Gillette® and Braun® will provide complimentary beauty and grooming treatments designed for all athletes to help them look and feel their best so they focus on giving their best when it matters most.
- Laundry Rooms supplied by Ariel: Athletes will experience outstanding cleaning performance when they bring their clothes and uniforms to the laundry rooms for cold water washing laundry services supplied by Ariel, the Official Laundry Product of Paris 2024.
- Dental Clinic with Oral-B® will give athletes the confidence of healthy smiles, offering athletes access to general and emergency dental services with high-performance Oral-B® toothbrushes, toothpastes and oral care education.
- Period Protection: Always and Tampax® will provide period protection products in the restrooms throughout the Athletes’ Village.
- P&G Everyday Champions Welcome Kit: Each athlete will receive a Paris-themed reusable bag equipped with P&G brand products such as Oral-B, Head & Shoulders, Aussie, Safeguard and Febreze to support their health and hygiene needs during Paris 2024.
“It’s incredible to see P&G brands recognize what matters most to athletes and show up for them during the Olympic and Paralympic Games in meaningful ways,” said Dame Laura Kenny, six-time Olympic medalist. “For athletes who are also juggling their role as a parent, connecting with their babies in an accessible space like the Village Nursery with Pampers will be an amazing resource, providing such valuable support to Olympic and Paralympic athletes during Games Time.”
P&G and P&G brands are also partnering with more than 100 of the world’s top-performing athletes, supporting their endeavors on and off the field of play in a variety of ways, through financial resources and even grant funding to their preferred charities through the Athletes for Good program. P&G’s full roster of athletes represents 17 countries and 37 sports and includes:
- Two-time Olympic Gold Medalist Clarisse Agbegnenou, Judo, France, partnering with Pampers, Ariel, and Oral-B;
- Olympic Gold Medalist Niek Kimmann, BMX, Netherlands, partnering with Gillette;
- Three-time Paralympic Gold Medalist Marie-Amélie Le Fur, Para athletics, France, partnering with Always;
- Paralympic Gold Medalist Alexis Hanquinquant, Para triathlon, France, partnering with Braun, Gillette, Head & Shoulders, and Oral-B;
- Paralympic Gold Medalist Anastasia Pagonis, Para swimming, USA, partnering with Venus;
- Two-time Olympic Medalist, Lydia Jacoby, Swimming, USA, partnering with Venus;
- Olympic Gold Medalist Wang Shun, Swimming, China, partnering with Safeguard.
About P&G’s Olympic & Paralympic Games Program
P&G has been a Worldwide Partner of the International Olympic Committee (IOC) since 2010. In July 2020, P&G announced the extension of its worldwide partnership with the Olympic Games through the LA28 Games, including global rights with the International Paralympic Committee (IPC) and the Paralympic Games. Since becoming a Worldwide Partner of the Olympic Games, the Company and its brands including Always®, Tide®, Ariel®, Gillette® and Head & Shoulders® have partnered with more than 500 athletes to shine a light on their daily commitment to be the best they can be, just as P&G brands commit to delivering superior performance for people who count on the brands in their everyday lives.
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit https://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit us at https://www.pg.com/news.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514255957/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
